MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

Hübner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Jückstock J, Nabieva N, Schneeweiss A, Tesch H, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Rack B (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Cancers MDPI

Book Volume: 14

Article Number: 1721

Journal Issue: 7

DOI: 10.3390/cancers14071721

Abstract

Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.

Authors with CRIS profile

Hanna Hübner Department of Obstetrics and Gynaecology Naiba Nabieva Department of Obstetrics and Gynaecology Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsklinikum Ulm DE Germany (DE) Universität Hamburg (UHH) DE Germany (DE) Kantonsspital St.Gallen CH Switzerland (CH) Klinikum der Universität München DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Agaplesion Markus Krankenhaus DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Heinrich-Heine-Universität Düsseldorf DE Germany (DE)

How to cite

APA:

Hübner, H., Häberle, L., Müller, V., Schrader, I., Lorenz, R., Forstbauer, H.,... Rack, B. (2022). MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers, 14(7). https://doi.org/10.3390/cancers14071721

MLA:

Hübner, Hanna, et al. "MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients." Cancers 14.7 (2022).

BibTeX: Download